Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases

@article{Brettschneider2009SerumAI,
  title={Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases},
  author={J. Brettschneider and T. Jaskowski and H. Tumani and Sana Abdul and J. Rose},
  journal={Journal of Neuroimmunology},
  year={2009},
  volume={217},
  pages={95-101}
}
  • J. Brettschneider, T. Jaskowski, +2 authors J. Rose
  • Published 2009
  • Medicine
  • Journal of Neuroimmunology
    • The serum level of IgM antibodies against Glc(alpha1,4)Glc(alpha) (GAGA4) is higher in relapsing remitting multiple sclerosis (RRMS) compared to other neurological disease (OND) patients and healthy controls (HC). Detecting the level of anti-GAGA4 antibody by enzyme immunoassay and total IgM, we confirmed that anti-GAGA4 IgM can differentiate RRMS from OND patients and HC. Moreover, secondary progressive MS (SPMS) and RRMS patients have similar levels of anti-GAGA4 demonstrating the biomarker's… CONTINUE READING
    View on Elsevier
    doi.org
    31 Citations
    Highly Influencial Citations
    1
    Background Citations
    8
    31 Citations
    Citation Type

    Citation Type

    Antibody profiling for the prognosis and diagnosis of multiple sclerosis in patients, compared with healthy subjects
    Evaluation of anti α-D-Glcp-(1→4)-α-D-Glcp (GAGA4) IgM antibodies as a biomarker for multiple sclerosis
    • 1
    • PDF
    Targets of the humoral autoimmune response in multiple sclerosis.
    • 69
    • Highly Influenced
    Investigation of autoantibody profiles for cerebrospinal fluid biomarker discovery in patients with relapsing–remitting multiple sclerosis
    • 18
    Serum Biomarker gMS-Classifier2: Predicting Conversion to Clinically Definite Multiple Sclerosis
    • 4
    • PDF
    Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis
    • 12
    Immunological differences between classical phenothypes of multiple sclerosis
    • 28
    Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
    • 36
    Autoantibodies as diagnostic biomarkers for the detection and subtyping of multiple sclerosis
    • 15
    The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.
    • 170

    References

    SHOWING 1-10 OF 32 REFERENCES
    Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.
    • 584
    • PDF
    Serum anti-Glc(α1,4)Glc(α) antibodies as a biomarker for relapsing–remitting multiple sclerosis
    • 48
    • Highly Influential
    Lack of association between antimyelin antibodies and progression to multiple sclerosis.
    • 146
    The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis
    • 57
    Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis.
    • 65
    • PDF
    Anti-α-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event
    • 32
    Clinically isolated syndromes
    • 130
    A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
    • 2,384
    Anti-S-Nitrosocysteine Antibodies Are a Predictive Marker for Demyelination in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis
    • 62
    • PDF
    IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
    • 1,784
    • PDF